6769 MESA RIDGE RD., SAN DIEGO, CA
Bylaws Amendment Approved; Role of Chairman Clarified at Inovio Pharmaceuticals
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Announces Pricing of $17.5 Million Public Offering
Other Events
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Inovio Pharmaceuticals Extends Series A Warrants Expiration to March 2026
FDA Accepts for Review BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
Announces Pricing of $25 Million Public Offering
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership